413 related articles for article (PubMed ID: 8882957)
1. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.
Hallek M; Langenmayer I; Nerl C; Knauf W; Dietzfelbinger H; Adorf D; Ostwald M; Busch R; Kuhn-Hallek I; Thiel E; Emmerich B
Blood; 1999 Mar; 93(5):1732-7. PubMed ID: 10029603
[TBL] [Abstract][Full Text] [Related]
3. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
[TBL] [Abstract][Full Text] [Related]
4. GM-CSF raises serum levels of beta 2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia.
Itälä M; Pelliniemi TT; Remes K
Br J Haematol; 1996 Jul; 94(1):129-32. PubMed ID: 8757522
[TBL] [Abstract][Full Text] [Related]
5. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia.
Di Giovanni S; Valentini G; Carducci P; Giallonardo P
Acta Haematol; 1989; 81(4):181-5. PubMed ID: 2502891
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia and prognostic factors.
Mozaheb Z; Hasanzadeh NazarAbadi MH; Aghaee MA
Asian Pac J Cancer Prev; 2012; 13(7):3009-13. PubMed ID: 22994703
[TBL] [Abstract][Full Text] [Related]
7. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia.
Stelmach P; Błoński JZ; Wawrzyniak E; Schweiger PE; Wilandt A; Majak PE; Robak T
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1321-1330. PubMed ID: 28100842
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.
Di Raimondo F; Giustolisi R; Lerner S; Cacciola E; O'Brien S; Kantarjian H; Keating MJ
Ann Oncol; 2001 May; 12(5):621-5. PubMed ID: 11432619
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia.
Reinisch W; Willheim M; Hilgarth M; Gasché C; Mader R; Szepfalusi S; Steger G; Berger R; Lechner K; Boltz-Nitulescu G
J Clin Oncol; 1994 Oct; 12(10):2146-52. PubMed ID: 7931486
[TBL] [Abstract][Full Text] [Related]
13. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia.
Knauf WU; Langenmayer I; Ehlers B; Mohr B; Adorf D; Nerl CH; Hallek M; Zwingers TH; Emmerich B; Thiel E
Leuk Lymphoma; 1997 Nov; 27(5-6):523-32. PubMed ID: 9477135
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.
Magnac C; Porcher R; Davi F; Nataf J; Payelle-Brogard B; Tang RP; Oppezzo P; Lévy V; Dighiero G; Ajchenbaum-Cymbalista F
Leukemia; 2003 Jan; 17(1):133-7. PubMed ID: 12529670
[TBL] [Abstract][Full Text] [Related]
16. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological significance of serum tumor markers in adult T-cell leukemia.
Sadamori N
Leuk Lymphoma; 1996 Aug; 22(5-6):415-9. PubMed ID: 8882954
[TBL] [Abstract][Full Text] [Related]
18. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of a scoring system based on clinical and biological parameters in early chronic lymphocytic leukemia.
Leotard S; Chastang C; Travade P; Jaudon MC; Tournilhac O; Baudet S; Merle-Beral H
Hematol J; 2000; 1(5):301-6. PubMed ID: 11920207
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers.
Christiansen I; Gidlöf C; Wallgren AC; Simonsson B; Tötterman TH
Blood; 1994 Nov; 84(9):3010-6. PubMed ID: 7949173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
